| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/22/2004 | US20040077634 Treatment of diseases characterized by excessive or insufficient cell death |
| 04/22/2004 | US20040077632 Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases |
| 04/22/2004 | US20040077630 Allosteric adenosine receptor modulators |
| 04/22/2004 | US20040077618 Epilepsy, bipolar disorder, psychiatric disorders, migraine, pain, neuroprotection, movement disorders; 2-methylcyclohexanecarboxamide, or 1,1':1',1''-ter(cyclopropane)-2'-carboxamide, or (cis)(2S)-2-((((3R,5S)-3,5-dimethylcyclohexyl) carbonyl)amino)propanoic acid for example |
| 04/22/2004 | US20040077617 for example 3-methylbicyclo[4.1.0]heptane-7-carboxylic acid or N-(2-amino-2-oxoethyl)-4,7,7-trimethyltricyclo [4.1.1.02,4]octane-3-carboxamide; use treating epilepsy, bipolar disorder, migraine, neuropathic and inflammatory pain |
| 04/22/2004 | US20040077616 Spirocyclopropyl amides and acids and their therapeutic applications |
| 04/22/2004 | US20040077615 Novel formulations for administering therapeutic lipophilic molecules |
| 04/22/2004 | US20040077599 Novel spiro[2.4]heptane amino carboxy compounds and derivatives thereof |
| 04/22/2004 | US20040077540 Permeabilizing peptide; reversibly enhancing paracellular transport; inhibits homotypic binding |
| 04/22/2004 | US20040077535 Novel physiologically active peptide and use thereof |
| 04/22/2004 | US20040077532 Aglyco products and methods of use |
| 04/22/2004 | US20040077525 Novel treatment |
| 04/22/2004 | US20040077079 Methods, kits and production plant for use in the production of cell colony forming units from a mammalian tissue explant and to the use of cells from such cell colony forming units in treatment of mammals suffering from tissue disorders |
| 04/22/2004 | US20040077007 Human SMN-like protein |
| 04/22/2004 | US20040076698 Drugs comprising plant extracts used for prevention amyloid formation, deposition or accumulation |
| 04/22/2004 | US20040076669 Tramadol-based medicament |
| 04/22/2004 | US20040076648 Antidepressant, an n-methyl-aspartic acid receptor antagonist, a lipophilic component, water and a surfacant; oil in water emulsion |
| 04/22/2004 | US20040076626 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| 04/22/2004 | US20040076614 For natural cellular immune defense in humans/animals; for foods/feeds |
| 04/22/2004 | US20040076601 Pharmaceutical form comprising a cell regulating factor and/or a cell proliferation promoter |
| 04/22/2004 | DE10246890A1 New C-(imidazo-(1,2-a)-pyridin-3-yl)-methylamines, are nitrogen monoxide synthase inhibitors useful e.g. for treating migraine, septic shock, neurodegenerative diseases, inflammatory pain or cancer |
| 04/22/2004 | DE10153346A1 Substituierte Indole Substituted indoles |
| 04/22/2004 | CA2501803A1 Thiazole compounds for the treatment of neurodegenerative disorders |
| 04/22/2004 | CA2501575A1 Inhibitors of fatty acid amide hydrolase |
| 04/22/2004 | CA2501348A1 Treatment of dementia and parkinson's disease |
| 04/22/2004 | CA2501347A1 Methods for the treatment of neurodegeneration |
| 04/22/2004 | CA2501082A1 Use of 5-ht2 receptor antagonists for the treatment of sleep disorders |
| 04/22/2004 | CA2499586A1 Antidiabetic beta-amino heterocyclic dipeptidyl peptidase inhibitors |
| 04/21/2004 | EP1411052A1 Benzo-fused 5-membered hetrocycle compounds,process for preparation of the same, and use thereof |
| 04/21/2004 | EP1410822A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 04/21/2004 | EP1410800A1 Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts |
| 04/21/2004 | EP1410798A2 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| 04/21/2004 | EP1410797A1 Solid oral dosage forms comprising valsartan |
| 04/21/2004 | EP1410796A2 New therapeutic uses for potassium channel openers |
| 04/21/2004 | EP1410038A2 Assays for identifying modulators of rhomboid polypeptides |
| 04/21/2004 | EP1410018A1 Method for detecting modultators of notch signalling |
| 04/21/2004 | EP1409737A2 Methods for detecting and treating the early onset of aging-related conditions |
| 04/21/2004 | EP1409715A2 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides |
| 04/21/2004 | EP1409680A2 Novel human proton-gated channels |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409675A1 Gene involved in apoptosis regulation |
| 04/21/2004 | EP1409660A2 Crystal structure of beta-site app cleaving enzyme (bace) and use thereof |
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409654A1 Immunological control of beta-amyloid levels in vivo |
| 04/21/2004 | EP1409645A1 Probiotic lactobacillus salivarius strains |
| 04/21/2004 | EP1409644A1 Probiotic bifidobacterium strains |
| 04/21/2004 | EP1409550A1 Extracellular messengers |
| 04/21/2004 | EP1409540A2 Melanocortin receptor ligands |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409531A2 Heterocarpine, a human ghrh-binding protein |
| 04/21/2004 | EP1409523A2 Pancam nucleic acids and polypeptides |
| 04/21/2004 | EP1409518A1 Use of fragments of oxytocin for the preparation of a pharmaceutical composition in order to create eustasis |
| 04/21/2004 | EP1409491A2 Thienopyrimidine-based inhibitors of the src family |
| 04/21/2004 | EP1409490A1 2-(aminomethyl)-tetrahydro-9-oxa-1,3-diaza-cyclopenta a]naphthalenyl derivatives with antipsychotic activity |
| 04/21/2004 | EP1409489A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 04/21/2004 | EP1409488A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 04/21/2004 | EP1409487A1 Pteridinones as kinase inhibitors |
| 04/21/2004 | EP1409485A1 Novel immunomodulating compounds |
| 04/21/2004 | EP1409483A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 04/21/2004 | EP1409477A1 Piperidine derivatives as nmda receptor antagonists |
| 04/21/2004 | EP1409476A1 Pharmaceutical compounds with serotonin receptor activity |
| 04/21/2004 | EP1409472A1 Method for the preparation of escitalopram |
| 04/21/2004 | EP1409467A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 04/21/2004 | EP1409463A1 N-heterocyclic inhibitors of tnf-alpha expression |
| 04/21/2004 | EP1409452A1 Sulfonamide derivatives |
| 04/21/2004 | EP1409450A1 N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| 04/21/2004 | EP1409449A1 Alpha-ketoglutarates of active ingredients and compositions containing same |
| 04/21/2004 | EP1409446A1 Method for the nitration of phenolic compounds |
| 04/21/2004 | EP1409102A1 Method and installation for setting in adsorbed state on a porous support active compounds contained in a product |
| 04/21/2004 | EP1409077A2 Thermotherapy via targeted delivery of nanoscale magnetic particles |
| 04/21/2004 | EP1409019A2 Gd3 synthesis inhibitors for treating neuropathological disorders |
| 04/21/2004 | EP1409015A1 Methods for treating or preventing skin disorders using cd2-binding agents |
| 04/21/2004 | EP1409006A2 Methods of treating diabetes mellitus |
| 04/21/2004 | EP1409005A1 Modulators of notch signalling for use in immunotherapy |
| 04/21/2004 | EP1409001A2 Mineral-protein preparations (mpp) and neuropathies in diabetes |
| 04/21/2004 | EP1409000A4 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1409000A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 04/21/2004 | EP1408995A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 04/21/2004 | EP1408986A2 Proteomimetic compounds and methods |
| 04/21/2004 | EP1408984A2 Organo-phosphorous compounds for activating gamma/delta t cells |
| 04/21/2004 | EP1408976A1 Treatment for attention-deficit hyperactivity disorder |
| 04/21/2004 | EP1408965A2 Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders |
| 04/21/2004 | EP1408964A2 Novel use of 2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts |
| 04/21/2004 | EP1408962A1 Substituted isoindoles and the use thereof |
| 04/21/2004 | EP1408959A1 Use of galiella lactone |
| 04/21/2004 | EP1408954A1 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 04/21/2004 | EP1408953A1 Carbamate compounds for use in preventing or treating bipolar disorder |
| 04/21/2004 | EP1408952A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders |
| 04/21/2004 | EP1408951A2 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers |
| 04/21/2004 | EP1408950A2 Methods of treating cytokine mediated diseases |
| 04/21/2004 | EP1408947A2 Fumaric acid derivatives as nf-kappab inhibitors |
| 04/21/2004 | EP1408943A2 Pharmaceutical formulation containing an ltb4 antagonist |
| 04/21/2004 | EP1408940A2 Pharmaceutical composition comprising deramciclane for the treatment of the decline and/or damage of cognitive functions |
| 04/21/2004 | EP1408938A1 Therapeutic strategies for prevention and treatment of alzheimer's disease |
| 04/21/2004 | EP1408936A2 Pharmaceutical composition |
| 04/21/2004 | EP1408911A1 Sustained-release therapeutic bioadhesive systems |
| 04/21/2004 | EP1408753A2 Compounds effecting neuron remodeling and assays for same |
| 04/21/2004 | EP1272481B1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 04/21/2004 | EP1242389B1 Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them |
| 04/21/2004 | EP1154987B1 Phenylalaninol derivatives |